XERS Q2 2025 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+48.8% YoY

Gross Profit

$57M79.6% margin

Operating Income

$4M6.3% margin

Net Income

-$2M-2.7% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+19.0%

Cash Flow

Operating Cash Flow

$182,000

Free Cash Flow

$10M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$335M

Total Liabilities

$354M

Stockholders' Equity

-$19M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$48M	+48.8%
Gross Profit	$57M	$38M	+51.6%
Operating Income	$4M	-$8M	+154.7%
Net Income	-$2M	-$15M	+87.2%

Revenue Segments

Product

$68M84%

Keveyis

$11M14%

Product, Other

$1M2%